Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Erb

Showing results (91-100 of 108) with videos related to

Pageof 11
Sort By:
Journal of Translational Medicine|January 18, 2024
New advances of the androgen receptor in prostate cancer: report from the 1st International Androgen Receptor SymposiumSherif Mehralivand, Christian Thomas, Martin Puhr, et al.
Life (Basel, Switzerland)|September 28, 2021
A Systematic Comparison of Antiandrogens Identifies Androgen Receptor Protein Stability as an Indicator for Treatment ResponseTiziana Siciliano, Ingo H Simons, Alicia-Marie K Beier, et al.
International Journal of Molecular Sciences|February 15, 2022
Impact of Androgen Receptor Activity on Prostate-Specific Membrane Antigen Expression in Prostate Cancer CellsUlrich Sommer, Tiziana Siciliano, Celina Ebersbach, et al.
Oncogenesis|May 30, 2017
The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signallingG Nappo, F Handle, F R Santer, et al.
Plos One|August 14, 2020
Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancerHolger H H Erb, Julia Bodenbender, Florian Handle, et al.
International Journal of Molecular Sciences|September 14, 2024
Prostate Cancer's Silent Partners: Fibroblasts and Their Influence on Glutamine Metabolism ManipulationPia V Hönscheid, Gustavo B Baretton, Martin Puhr, et al.
Endocrine-Related Cancer|August 6, 2013
IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9Holger H H Erb, Regina V Langlechner, Patrizia L Moser, et al.
Molecular Cancer Therapeutics|June 29, 2011
Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell linesFrédéric R Santer, Philipp P S Höschele, Su Jung Oh, et al.
European Urology|June 20, 2018
Fractionated Radiation of Primary Prostate Basal Cells Results in Downplay of Interferon Stem Cell and Cell Cycle Checkpoint SignaturesFabian Guggenberger, Harmen J G van de Werken, Holger H H Erb, et al.
Molecular Cancer Therapeutics|September 27, 2018
The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate ModelsFlorian Handle, Martin Puhr, Georg Schaefer, et al.
Pageof 11

Showing results (91-100 of 108) with videos related to

Sort By:
Pageof 11
Journal of Translational Medicine|January 18, 2024
New advances of the androgen receptor in prostate cancer: report from the 1st International Androgen Receptor SymposiumSherif Mehralivand, Christian Thomas, Martin Puhr, et al.
Life (Basel, Switzerland)|September 28, 2021
A Systematic Comparison of Antiandrogens Identifies Androgen Receptor Protein Stability as an Indicator for Treatment ResponseTiziana Siciliano, Ingo H Simons, Alicia-Marie K Beier, et al.
International Journal of Molecular Sciences|February 15, 2022
Impact of Androgen Receptor Activity on Prostate-Specific Membrane Antigen Expression in Prostate Cancer CellsUlrich Sommer, Tiziana Siciliano, Celina Ebersbach, et al.
Oncogenesis|May 30, 2017
The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signallingG Nappo, F Handle, F R Santer, et al.
Plos One|August 14, 2020
Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancerHolger H H Erb, Julia Bodenbender, Florian Handle, et al.
International Journal of Molecular Sciences|September 14, 2024
Prostate Cancer's Silent Partners: Fibroblasts and Their Influence on Glutamine Metabolism ManipulationPia V Hönscheid, Gustavo B Baretton, Martin Puhr, et al.
Endocrine-Related Cancer|August 6, 2013
IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9Holger H H Erb, Regina V Langlechner, Patrizia L Moser, et al.
Molecular Cancer Therapeutics|June 29, 2011
Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell linesFrédéric R Santer, Philipp P S Höschele, Su Jung Oh, et al.
European Urology|June 20, 2018
Fractionated Radiation of Primary Prostate Basal Cells Results in Downplay of Interferon Stem Cell and Cell Cycle Checkpoint SignaturesFabian Guggenberger, Harmen J G van de Werken, Holger H H Erb, et al.
Molecular Cancer Therapeutics|September 27, 2018
The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate ModelsFlorian Handle, Martin Puhr, Georg Schaefer, et al.
Pageof 11